HIV Treatment Bulletin - Vol. 7, No. 3, March 2006

This year CROI was generally an optimistic conference, with studies on new drugs, a few news studies on side effects and lipodystrophy, and a range of other interesting smaller studies. The presentation of the SMART study provided sufficient new data to restart discussions on treatment interruptions, large-scale research, and by implications, the optimal timing for initial treatment.

CROI also provides some of the best online support for people unable to attend the meeting. Abstracts are online already, and are searchable by subject or author. Webcasts are routinely provided of the plenary talks, and this year for the first time, are also provided for the most important oral scientific presentations. These online presentations, including slides, can also me downloaded as mp3 audio files or podcasts.

The 13th Conference on Retroviruses and Opportunistic Infections

Reports in this issue of HTB from CROI include:

• Early integrase inhibitor studies in treatment experienced patients raise hopes for new drugs in a new class
• Atazanavir in treatment naïve patients, with and without ritonavir boosting
• Summary of STI studies: SMART shows clear increased risk from interrupting treatment at any CD4 count
• The effect of repeated single-dose nevirapine for PMTCT in a second pregnancy
• Should the criteria for initiation of HAART be revisited in pregnant women?
• Cotrimoxazole prophylaxis in pregnancy
• CNS penetration of ARV drugs is associated with lower CSF viral load
• Sexually transmission of hepatitis C in HIV-positive men in the UK
• D:A:D study shows that PIs rather than NNRTIs drive the previously reported cardiovascular risk of combinatio antiretroviral therapy
• Interventions for the management of lipodystrophy and metabolic complications

Further reports from CROI will also be included in the April issue of HTB.

Many other community organisations provide in depth rapid reports form the meeting, including

The National AIDS Treatment Advocacy Project's - NATAP
http://www.natap.org

The Body
http://www.thebody.com

HIV and Hepatitis.com
http://www.hivandhepatitis.com

NAM
http://www.aidsmap.com

Clinical Care Options
http://www.clinicalcareoptions.com

060310
IB060703-01

©2006. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.